{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:58:47Z","timestamp":1790816327507,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,10,14]],"date-time":"2016-10-14T00:00:00Z","timestamp":1476403200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Imaging Biol"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s11307-016-1018-x","type":"journal-article","created":{"date-parts":[[2016,10,14]],"date-time":"2016-10-14T14:16:19Z","timestamp":1476454579000},"page":"437-445","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Predictive Value of Asphericity in Pretherapeutic [111In]DTPA-Octreotide SPECT\/CT for Response to Peptide Receptor Radionuclide Therapy with [177Lu]DOTATATE"],"prefix":"10.1007","volume":"19","author":[{"given":"Christoph","family":"Wetz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Apostolova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. G.","family":"Steffen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Hofheinz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Furth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Kupitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Ruf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Venerito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Klose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Amthauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,14]]},"reference":[{"key":"1018_CR1","doi-asserted-by":"publisher","first-page":"481","DOI":"10.7150\/thno.4024","volume":"2","author":"M Fani","year":"2012","unstructured":"Fani M, Maecke HR, Okarvi SM (2012) Radiolabeled peptides: valuable tools for the detection and treatment of cancer. Theranostics 2:481\u2013501","journal-title":"Theranostics"},{"key":"1018_CR2","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","volume":"378","author":"ME Pavel","year":"2011","unstructured":"Pavel ME, Hainsworth JD, Baudin E et al (2011) Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 378:2005\u20132012","journal-title":"Lancet"},{"key":"1018_CR3","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1200\/JCO.2005.08.066","volume":"23","author":"DJ Kwekkeboom","year":"2005","unstructured":"Kwekkeboom DJ, Teunissen JJ, Bakker WH et al (2005) Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 23:2754\u20132762","journal-title":"J Clin Oncol"},{"key":"1018_CR4","doi-asserted-by":"publisher","first-page":"4S","DOI":"10.1200\/jco.2016.34.4_suppl.194","volume":"34","author":"J Strosberg","year":"2016","unstructured":"Strosberg J, Wolin E, Chasen B et al (2016) Progression-free survival, radiographic response, and preliminary overall survival results in patients with midgut neuroendocrine tumors treated with 177Lu-Dotatate [abstract]. J Clin Oncol 34:4S","journal-title":"J Clin Oncol"},{"key":"1018_CR5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1159\/000371804","volume":"101","author":"M Koerner","year":"2015","unstructured":"Koerner M, Waser B, Reubi JC (2015) Does somatostatin or gastric inhibitory peptide receptor expression correlate with tumor grade and stage in gut neuroendocrine tumors. Neuroendocrinology 101:45\u201357","journal-title":"Neuroendocrinology"},{"key":"1018_CR6","doi-asserted-by":"publisher","first-page":"858","DOI":"10.2967\/jnumed.108.057505","volume":"50","author":"E Garin","year":"2009","unstructured":"Garin E, Le Jeune F, Devillers A et al (2009) Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors. J Nucl Med 50:858\u2013864","journal-title":"J Nucl Med"},{"key":"1018_CR7","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1148\/rg.352140164","volume":"35","author":"MS Hofman","year":"2015","unstructured":"Hofman MS, Lau WFE, Hicks RJ (2015) Somatostatin receptor imaging with 68Ga DOTATATE PET\/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiographics 35:500\u2013516","journal-title":"Radiographics"},{"key":"1018_CR8","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s11307-014-0795-3","volume":"17","author":"C Kratochwil","year":"2014","unstructured":"Kratochwil C, Stefanova M, Mavriopoulou E et al (2014) SUV of [68Ga]DOTATOC-PET\/CT predicts response probability of PRRT in neuroendocrine tumors. Mol Imaging Biol 17:313\u2013318","journal-title":"Mol Imaging Biol"},{"key":"1018_CR9","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3748\/wjg.v20.i1.118","volume":"20","author":"T-T Li","year":"2014","unstructured":"Li T-T, Qiu F, Qian ZR et al (2014) Classification, clinicopathologic features and treatment of gastric neuroendocrine tumors. World J Gastroenterol 20:118\u2013125","journal-title":"World J Gastroenterol"},{"key":"1018_CR10","doi-asserted-by":"publisher","unstructured":"Apostolova I, Ego K, Steffen IG et al (2016) The asphericity of the metabolic tumour volume in NSCLC: correlation with histopathology and molecular markers. Eur J Nucl Med Mol Imaging. doi:\n10.1007\/s00259-016-3452-z","DOI":"10.1007\/s00259-016-3452-z"},{"key":"1018_CR11","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s13244-012-0196-6","volume":"3","author":"F Davnall","year":"2012","unstructured":"Davnall F, Yip CS, Ljungqvist G et al (2012) Assessment of tumor heterogeneity: an emerging imaging tool for clinical practice? Insights Imaging 3:573\u2013589","journal-title":"Insights Imaging"},{"key":"1018_CR12","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1097\/PAS.0b013e31821a0696","volume":"35","author":"Z Yang","year":"2011","unstructured":"Yang Z, Tang LH, Klimstra DS (2011) Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification. Am J Surg Pathol 35:853\u2013860","journal-title":"Am J Surg Pathol"},{"key":"1018_CR13","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.nucmedbio.2014.12.006","volume":"42","author":"C Lapa","year":"2015","unstructured":"Lapa C, Werner RA, Schmid JS et al (2015) Prognostic value of positron emission tomography-assessed tumor heterogeneity in patients with thyroid cancer undergoing treatment with radiopeptide therapy. Nucl Med Biol 42:349\u2013354","journal-title":"Nucl Med Biol"},{"key":"1018_CR14","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1016\/0024-3205(91)90052-D","volume":"49","author":"WH Bakker","year":"1991","unstructured":"Bakker WH, Albert R, Bruns C et al (1991) [111In-DTPA-D-PHE1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation. Life Sci 49:1583\u20131591","journal-title":"Life Sci"},{"key":"1018_CR15","first-page":"223","volume":"47","author":"S Ezziddin","year":"2006","unstructured":"Ezziddin S, Logvinski T, Yong-Hing C et al (2006) Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors. J Nucl Med 47:223\u2013233","journal-title":"J Nucl Med"},{"key":"1018_CR16","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1136\/gutjnl-2011-300831","volume":"61","author":"JK Ramage","year":"2012","unstructured":"Ramage JK, Ahmed A, Ardill J et al (2012) Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut 61:6\u201332","journal-title":"Gut"},{"key":"1018_CR17","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1007\/s00330-014-3269-8","volume":"24","author":"I Apostolova","year":"2014","unstructured":"Apostolova I, Steffen IG, Wedel F et al (2014) Asphericity of pretherapeutic tumour FDG uptake provides independent prognostic value in head-and-neck cancer. Eur Radiol 24:2077\u20132087","journal-title":"Eur Radiol"},{"key":"1018_CR18","first-page":"125","volume":"55","author":"I Apostolova","year":"2014","unstructured":"Apostolova I, Steffen IG, Rogasch J et al (2014) Predictive value of asphericity of pretherapeutic FDG uptake in NSCLC. J Nucl Med 55:125\u2013125","journal-title":"J Nucl Med"},{"key":"1018_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-896","author":"I Apostolova","year":"2014","unstructured":"Apostolova I, Rogasch J, Buchert R et al (2014) Quantitative assessment of the asphericity of pretherapeutic FDG uptake as an independent predictor of outcome in NSCLC. BMC Cancer. doi:\n10.1186\/1471-2407-14-896","journal-title":"BMC Cancer"},{"key":"1018_CR20","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s00259-014-2953-x","volume":"42","author":"F Hofheinz","year":"2015","unstructured":"Hofheinz F, Lougovski A, Z\u00f6phel K et al (2015) Increased evidence for the prognostic value of primary tumor asphericity in pretherapeutic FDG PET for risk stratification in patients with head and neck cancer. Eur J Nucl Med Mol Imaging 42:429\u2013437","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1018_CR21","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.wear.2010.01.021","volume":"268","author":"JA Warner","year":"2010","unstructured":"Warner JA, Gladkis LG, Geruschke T et al (2010) Tracing wear debris pathways via ion-implanted indium-111. Wear May 268:1257\u20131265","journal-title":"Wear May"},{"key":"1018_CR22","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1159\/000225946","volume":"90","author":"DJ Kwekkeboom","year":"2009","unstructured":"Kwekkeboom DJ, Krenning EP, Scheidhauer K et al (2009) ENETS consensus guidelines for the standards of care in neuroendocrine tumors: somatostatin receptor imaging with 111In-pentetreotide. Neuroendocrinology 90:184\u2013189","journal-title":"Neuroendocrinology"},{"key":"1018_CR23","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1097\/SLA.0b013e3181fd37e8","volume":"252","author":"A Frilling","year":"2010","unstructured":"Frilling A, Sotiropoulos GC, Radtke A et al (2010) The impact of 68Ga-DOTATOC positron emission tomography\/computed tomography on the multimodal management of patients with neuroendocrine tumors. Ann Surg 252:850\u2013856","journal-title":"Ann Surg"},{"key":"1018_CR24","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1007\/s00066-008-1849-8","volume":"184","author":"M Pech","year":"2008","unstructured":"Pech M, Mohnike K, Wieners G et al (2008) Radiotherapy of liver metastases. Strahlenther Onkol 184:256\u2013261","journal-title":"Strahlenther Onkol"},{"key":"1018_CR25","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"},{"key":"1018_CR26","doi-asserted-by":"publisher","first-page":"082503","DOI":"10.1118\/1.4812892","volume":"40","author":"F Hofheinz","year":"2013","unstructured":"Hofheinz F, Langner J, Petr J et al (2013) An automatic method for accurate volume delineation of heterogeneous tumors in PET. Med Phys 40:082503","journal-title":"Med Phys"},{"key":"1018_CR27","first-page":"9","volume":"511","author":"F Hofheinz","year":"2012","unstructured":"Hofheinz F, P\u00f6tzsch C, Oehme L et al (2012) Automatic volume delineation in oncological PET. Evaluation of a dedicated software tool and comparison with manual delineation in clinical data sets. Nucl Med 511:9\u201316","journal-title":"Nucl Med"},{"key":"1018_CR28","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2217\/ije.14.40","volume":"2","author":"JE Maxwell","year":"2015","unstructured":"Maxwell JE, Howe JR (2015) Imaging in neuroendocrine tumors: an update for the clinician. International Journal of Endocrine Oncology 2:159\u2013168","journal-title":"International Journal of Endocrine Oncology"},{"key":"1018_CR29","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s002590050034","volume":"27","author":"JC Reubi","year":"2000","unstructured":"Reubi JC, Schaer JC, Waser B et al (2000) Affinity profiles for human somatostatin receptor subtypes SST1\u2013SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 27:273\u2013282","journal-title":"Eur J Nucl Med"},{"key":"1018_CR30","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1097\/RLU.0000000000001096","volume":"41","author":"GS Limouris","year":"2015","unstructured":"Limouris GS, Poulantzas V, Trompoukis N et al (2015) Comparison of 111In-[DTPA0] octreotide versus non carrier added 177Lu-[DOTA0, Tyr3]-octreotate efficacy in patients with GEP-NET treated intra-arterially for liver metastases. Clin Nucl Med 41:194\u2013200","journal-title":"Clin Nucl Med"},{"key":"1018_CR31","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1097\/MPA.0b013e3181ec124e","volume":"39","author":"DS Klimstra","year":"2010","unstructured":"Klimstra DS, Modlin IR, Domenico C et al (2010) The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 39:707\u2013712","journal-title":"Pancreas"},{"key":"1018_CR32","doi-asserted-by":"publisher","first-page":"875","DOI":"10.2967\/jnumed.109.066134","volume":"51","author":"R Srirajaskanthan","year":"2010","unstructured":"Srirajaskanthan R, Kayani I, Quigley AM et al (2010) The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy. J Nucl Med 51:875\u2013882","journal-title":"J Nucl Med"}],"container-title":["Molecular Imaging and Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-016-1018-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11307-016-1018-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-016-1018-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,4,26]],"date-time":"2017-04-26T16:30:50Z","timestamp":1493224250000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11307-016-1018-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,14]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["1018"],"URL":"https:\/\/doi.org\/10.1007\/s11307-016-1018-x","relation":{},"ISSN":["1536-1632","1860-2002"],"issn-type":[{"value":"1536-1632","type":"print"},{"value":"1860-2002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,14]]}}}